http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110882257-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2019-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110882257-B |
| titleOfInvention | A kind of use of ergosterol combined with gefitinib |
| abstract | The invention relates to a combined drug for treating non-small cell lung cancer, in particular to the use of ergosterol combined with gefitinib. It belongs to the field of biomedical technology. By culturing lung cancer A549 cells and PC-9 cells in vitro, the inhibitory effect of drugs on tumors was studied. Two cell lines (GEF-sensitive PC-9 cells and drug-resistant A549 cells, respectively) were used to conduct MTT assay; Hochest33258 cell apoptosis assay; flow cytometry to detect cell apoptosis and cell cycle; Western-blots assay to investigate Effects of cellular EGFR signaling pathway. Preliminary discussion on whether the combination of ERG and GEF has a synergistic anti-lung cancer effect, whether it can achieve synergistic and sensitizing effects on sensitive cell lines, whether it can increase the sensitivity of drug-resistant cell lines, and its therapeutic effect on non-small cell lung cancer and mechanism research. |
| priorityDate | 2019-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.